Global Genes

The purpose of the webinar was to provide the Epidermolysis Bullosa community with accurate and up to date information on the results of the phase three trial of SD-101. As you know, on September 13th, 2017 Amicus Therapeutics Announced that top-line data from the randomized, double-blind, placebo-controlled Phase 3 clinical study (ESSENCE, SD-005) to assess the efficacy and safety of the novel topical wound-healing agent SD-101 did not meet the primary endpoints or secondary endpoints in participants with epidermolysis bullosa (EB). Amicus Therapeutics is committed to ensuring that the Epidermolysis Bullosa community is provided with the results of the phase three trial of SD-101 and would like the opportunity to present this information to the community via webinar.